Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRON Cronos Group	$2.56 -4.1%	$2.02	$1.60 ▼ $2.77	$982.55M	1.01	1.75 million shs	8.54 million shs
CTMX CytomX Therapeutics	$1.86 -19.5%	$2.40	$0.40 ▼ $3.10	$149.95M	2.13	3.16 million shs	11.17 million shs
PHAR Pharming Group	$11.30 -6.6%	$10.90	$6.73 ▼ $17.08	$774.16M	0.02	5,983 shs	14,628 shs
QURE uniQure	$14.30 +1.3%	$14.68	$4.45 ▼ $19.18	$784.64M	0.11	1.40 million shs	879,171 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRON Cronos Group	+16.09%	+32.18%	+27.75%	+30.88%	+21.36%
CTMX CytomX Therapeutics	-1.70%	-3.35%	-4.55%	-7.60%	+92.50%
PHAR Pharming Group	-8.54%	-1.22%	+20.40%	+21.00%	+51.25%
QURE uniQure	+6.11%	+2.33%	-2.15%	+10.00%	+97.08%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRON Cronos Group	1.4057 of 5 stars	0.0	5.0	0.0	2.5	0.0	1.3
CTMX CytomX Therapeutics	4.0178 of 5 stars	3.5	1.0	4.7	1.7	1.7	1.3
PHAR Pharming Group	2.8231 of 5 stars	3.5	5.0	0.0	2.5	0.0	0.6
QURE uniQure	2.0796 of 5 stars	3.5	2.0	0.0	0.6	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRON Cronos Group	0.00	N/A	N/A	N/A
CTMX CytomX Therapeutics	3.00	Buy	$5.75	209.14% Upside
PHAR Pharming Group	3.00	Buy	$30.00	165.49% Upside
QURE uniQure	2.91	Moderate Buy	$36.55	155.56% Upside

Current Analyst Ratings Breakdown

Latest CTMX, QURE, PHAR, and CRON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/31/2025	CTMX CytomX Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
7/30/2025	QURE uniQure	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$47.00
7/29/2025	QURE uniQure	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$38.00 ➝ $35.00
5/30/2025	QURE uniQure	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00
5/29/2025	QURE uniQure	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00
5/19/2025	QURE uniQure	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/15/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$2.50 ➝ $5.00
5/15/2025	CTMX CytomX Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$5.00 ➝ $5.00
5/12/2025	CTMX CytomX Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00 ➝ $6.00
5/12/2025	QURE uniQure	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
5/12/2025	QURE uniQure	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRON Cronos Group	$117.61M	8.35	N/A	N/A	$2.90 per share	0.88
CTMX CytomX Therapeutics	$138.10M	1.09	$0.29 per share	6.49	($0.01) per share	-186.00
PHAR Pharming Group	$297.20M	2.60	$0.06 per share	178.48	$3.25 per share	3.48
QURE uniQure	$27.12M	28.93	N/A	N/A	($0.14) per share	-102.14

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRON Cronos Group	$41.08M	$0.05	51.20	85.33	N/A	14.19%	-3.78%	-3.62%	N/A
CTMX CytomX Therapeutics	$31.87M	$0.56	3.32	N/A	N/A	34.04%	158.70%	36.04%	N/A
PHAR Pharming Group	-$11.84M	-$0.13	N/A	376.67	N/A	-2.19%	-3.31%	-1.78%	10/23/2025 (Estimated)
QURE uniQure	-$239.56M	-$3.92	N/A	N/A	N/A	-1,387.98%	-1,010.74%	-33.27%	N/A

Latest CTMX, QURE, PHAR, and CRON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	CRON Cronos Group	-$0.02	-$0.10	-$0.08	-$0.10	$45.73 million	$33.46 million
7/31/2025	Q2 2025	PHAR Pharming Group	-$0.10	$0.06	+$0.16	$0.06	$70.36 million	$93.20 million
7/29/2025	Q2 2025	QURE uniQure	-$0.89	-$0.69	+$0.20	-$0.69	$5.00 million	$5.26 million
5/12/2025	Q1 2025	CTMX CytomX Therapeutics	$0.18	$0.27	+$0.09	$0.27	$35.42 million	$50.92 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRON Cronos Group	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A
QURE uniQure	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRON Cronos Group	N/A	24.65	23.53
CTMX CytomX Therapeutics	N/A	4.20	4.20
PHAR Pharming Group	0.38	2.79	2.07
QURE uniQure	1.53	9.98	9.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRON Cronos Group	8.71%
CTMX CytomX Therapeutics	67.77%
PHAR Pharming Group	0.03%
QURE uniQure	78.83%

Insider Ownership

Company	Insider Ownership
CRON Cronos Group	6.90%
CTMX CytomX Therapeutics	6.60%
PHAR Pharming Group	2.07%
QURE uniQure	4.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRON Cronos Group	450	383.81 million	357.32 million	Optionable
CTMX CytomX Therapeutics	170	80.62 million	75.30 million	Optionable
PHAR Pharming Group	280	68.51 million	67.10 million	Not Optionable
QURE uniQure	500	54.87 million	52.24 million	Optionable

CTMX, QURE, PHAR, and CRON Headlines

Recent News About These Companies

uniQure (NASDAQ:QURE) Upgraded at Wall Street Zen

August 4, 2025 | americanbankingnews.com

Cantor Fitzgerald Predicts Weaker Earnings for uniQure

August 3, 2025 | americanbankingnews.com

Leerink Partnrs Has Bullish Estimate for uniQure Q3 Earnings

August 3, 2025 | americanbankingnews.com

William Blair Has Positive Outlook for uniQure Q3 Earnings

August 3, 2025 | americanbankingnews.com

What is HC Wainwright's Forecast for uniQure Q3 Earnings?

August 2, 2025 | americanbankingnews.com

Wall Street Analysts Think uniQure (QURE) Could Surge 142.67%: Read This Before Placing a Bet

July 31, 2025 | zacks.com

uniQure N.V. (QURE) Q2 2025 Earnings Call Transcript

July 29, 2025 | seekingalpha.com

uniQure Narrows Loss in Fiscal Q2

July 29, 2025 | fool.com

uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates

July 29, 2025 | zacks.com

uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress

July 29, 2025 | globenewswire.com

uniQure to Announce Second Quarter 2025 Financial Results

July 22, 2025 | globenewswire.com

uniQure: Price And Value Have Caught Up

June 17, 2025 | seekingalpha.com

uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer

June 11, 2025 | globenewswire.com

uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease

June 2, 2025 | globenewswire.com

3 Top Genomics Stocks to Add to Your Portfolio in 2025

May 21, 2025 | zacks.com

Wall Street Analysts See a 161.51% Upside in uniQure (QURE): Can the Stock Really Move This High?

May 14, 2025 | zacks.com

uniQure N.V. (QURE) Q1 2025 Earnings Call Transcript

May 9, 2025 | seekingalpha.com

UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates

May 9, 2025 | zacks.com

uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress

May 9, 2025 | globenewswire.com

uniQure to Announce First Quarter 2025 Financial Results

May 5, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CTMX, QURE, PHAR, and CRON Company Descriptions

Cronos Group NASDAQ:CRON

$2.56 -0.11 (-4.12%)

Closing price 04:00 PM Eastern

Extended Trading

$2.56 +0.00 (+0.20%)

As of 05:38 PM Eastern

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

CytomX Therapeutics NASDAQ:CTMX

$1.86 -0.45 (-19.48%)

Closing price 04:00 PM Eastern

Extended Trading

$1.90 +0.04 (+2.15%)

As of 05:39 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Pharming Group NASDAQ:PHAR

$11.30 -0.80 (-6.61%)

Closing price 04:00 PM Eastern

Extended Trading

$11.33 +0.03 (+0.27%)

As of 04:10 PM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

uniQure NASDAQ:QURE

$14.30 +0.18 (+1.27%)

Closing price 04:00 PM Eastern

Extended Trading

$14.32 +0.02 (+0.13%)

As of 05:20 PM Eastern

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time